Cryo-Cell International Profit Margin

Cryo-Cell International (CCEL) currently reports a profit margin of -9.05% as of August 2026. That compares with 1.26% in the prior-year period — down 819.4% year over year. That is below the Healthcare sector average of 19.13%. Use the charts on this page to explore Cryo-Cell International's profit margin history and peer comparisons.

Cryo-Cell International's profit margin decreased from 1.26% to -9.05% — a 819.4% year-over-year decrease (period ending August 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cryo-Cell International's profit margin of -9.05% is lower than the Healthcare sector average of 19.13%. That is roughly 147.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Cryo-Cell International's current -9.05% should be judged against Healthcare norms (sector average: 19.13%) and against CCEL's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -9.05%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 19.13%. From there, open related valuation or income-statement pages for Cryo-Cell International, and consider following CCEL for alerts when major investors trade the stock.